My watch list

Certolizumab pegol

The introduction to this article provides insufficient context for those unfamiliar with the subject.
Please help improve the article with a good introductory style.

Certolizumab pegol (CDP870) (proposed tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.

Additional recommended knowledge

Daily Visual Balance Check

Weighing the right way

Don't let static charges disrupt your weighing accuracy

It is the subject of phase III clinical trials in both Crohn's disease^[1] and rheumatoid arthritis. ^[2]

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.

In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.

References

^ Sandborn WJ, Feagan BG, Stoinov S, et al (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228-38. doi:10.1056/NEJMoa067594. PMID 17634458.
^ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy 5 (4): 601-6. doi:10.1517/14712598.5.4.601. PMID 15934837.

v • d • e Humanized monoclonal antibodies
Cancer	Alemtuzumab, Apolizumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab
Immunosuppression	Aselizumab, Atlizumab, Cedelizumab, Daclizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
Viral infections	Felvizumab, Palivizumab, PRO 140
other	Bapineuzumab, Certolizumab pegol, Eculizumab, Motavizumab, Natalizumab, Ocrelizumab, Omalizumab, Ranibizumab, Tadocizumab, Tefibazumab, Tucotuzumab celmoleukin, Urtoxazumab